Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SH: 600276) unveiled its half-year financial report in August 2026, and the mid-year scorecard, which had generated considerable market anticipation, fell short of the optimistic forecasts surrounding a potential resurgence in high-growth momentum for the innovative drug frontrunner.

The company recorded total revenue of RMB 15.456 billion for the first half, reflecting a 1.9% year-on-year decline compared to RMB 15.761 billion in the same period of 2025. Net profit attributable to shareholders came in at RMB 4.465 billion, marking a marginal 0.3% increase from the prior year. This trajectory of shrinking revenue alongside essentially stagnant profit stands in stark contrast to earlier market projections.

Looking back at the full-year 2025 results, revenue reached RMB 31.629 billion, up just 13.02% year-on-year, while net profit attributable to shareholders was RMB 7.711 billion, with relatively subdued growth. A closer examination reveals that the company is grappling with slowing revenue expansion and nearly halted profit growth on the operational front, while simultaneously navigating a series of regulatory enforcement actions—spanning historical financial rectifications, executive misconduct in trading, and overseas production compliance failures. These challenges are compounded by intensifying competition within the domestic innovative drug arena and slower-than-anticipated FDA approval progress overseas. The former "domestic pharma leader" now faces triple development pressures across earnings performance, regulatory compliance, and international expansion, with its competitive edge among industry leaders showing signs of erosion.

Weak Growth Momentum in Financial Data

Disaggregating the complete financial cycle reveals that Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s earnings quality has been subpar over the past two years, with core business growth momentum lacking vitality and multiple metrics pointing to operational strain. In the full-year 2025 report, revenue climbed 13.02% from RMB 27.985 billion in 2024 to RMB 31.629 billion, while net profit attributable to shareholders rose 21.68% from RMB 6.337 billion to RMB 7.711 billion.

Although the profit growth rate appears to outpace revenue, the incremental gains are heavily reliant on accounting adjustments rather than improved profitability from core operations. Throughout 2025, sales expenses remained persistently elevated, with promotional, academic, and channel-related expenditures staying at high levels, continuously squeezing profit margins. Growth in key oncology products slowed prematurely, and several once-blockbuster innovative drugs experienced declining sales volumes due to medical insurance price cuts and competitive pressures. The 2026 interim report further underscores the fundamental growth challenges. First-half revenue of RMB 15.456 billion slipped 1.9% from RMB 15.761 billion in the year-ago period, marking a phase of negative half-year revenue growth.

Breaking down the revenue structure, licensing income—a key contributor to revenue growth—dropped sharply to RMB 1.422 billion in the first half of 2026, down 28.6% from RMB 1.991 billion in the corresponding period of 2025, indicating a narrowing of overseas collaboration monetization channels. The innovative drug segment generated RMB 8.809 billion, up 16.4% year-on-year, but this growth relied solely on small-scale ramp-ups of multiple low-priced new products. Growth in established anti-tumor drugs has largely plateaued, with the flagship product camrelizumab continuing to lose market share to similar PD-1 inhibitors from BeiGene and Innovent Biologics, thereby limiting its single-product revenue expansion. The generic drug segment has been persistently impacted by successive rounds of national centralized procurement, with average price cuts exceeding 70% for winning bids, significantly compressing profit margins on existing products. Following the company's proactive contraction of its generic pipeline, no new revenue streams have emerged to fill the gap.

Notably, the meager 0.3% profit growth falls far short of matching the company's substantial annual R&D expenditures. In 2025, Jiangsu Hengrui Pharmaceuticals Co., Ltd. invested RMB 8.724 billion in R&D, accounting for 27.58% of total annual revenue. These substantial funds were dispersed across over a hundred pipeline projects, with resources spread thinly, and no blockbuster product with market-leading competitiveness at the RMB 10-billion scale has yet materialized. R&D spending continued to escalate in the first half of 2026, but the lengthy commercialization cycle for new products means these investments cannot translate into near-term revenue gains. In industry comparisons, BeiGene and Innovent Biologics have achieved rapid performance breakthroughs through single core products, whereas Jiangsu Hengrui Pharmaceuticals Co., Ltd. exhibits a "broad portfolio, low returns" R&D profile, lagging peers in input-output efficiency.

The long-term impact of centralized procurement policies remains a critical factor pressuring revenue growth. The company has had 35 generic drugs included in national procurement schemes, with 22 products winning bids at an average price reduction of 74.5%. Ongoing procurement renewals in 2025 and 2026, coupled with local supplementary procurement initiatives, continue to erode profit margins on existing drugs. After innovative drugs enter medical insurance negotiations, prices are cut by an average of over 30%, and under these volume-price adjustments, revenue scale growth is constrained, with profits barely maintained through operational cost reductions. The medium-to-long-term profit growth outlook is trending toward stabilization.

Compliance Management Shortfalls

As a long-established A-share pharmaceutical company, Jiangsu Hengrui Pharmaceuticals Co., Ltd. has encountered multiple compliance issues over the years, ranging from improper financial accounting and executive illegal trading to inadequate overseas production compliance controls. These regulatory records highlight areas for improvement within the company's internal control system.

In April 2021, the Ministry of Finance issued its 40th announcement on accounting information quality inspections, imposing a RMB 50,000 administrative penalty on Jiangsu Hengrui Pharmaceuticals Co., Ltd. for large-scale irregularities involving the use of fraudulent invoices to divert funds, totaling RMB 4.199 million. In 2018, the company was found to have improperly used non-company airfare and toll invoices to reimburse expert lecture fees and academic promotion expenses totaling RMB 1.088 million. Additionally, RMB 2.1491 million in employee welfare bonuses were recorded through fabricated consulting and advertising invoices, while RMB 961,900 in sales subsidies and client gifts were reimbursed using off-site bridge toll invoices by subordinate offices. These practices formed an off-book capital flow chain, using irregular invoices to extract funds for pharmaceutical academic promotions—a marketing approach not uncommon in the industry historically.

Regulatory scrutiny explicitly noted that the company's bookkeeping was non-standard and financial accounting contained irregularities, with internal audit oversight failing to fully function. Although the penalties were modest, the millions of yuan in irregular reimbursements underscore systemic deficiencies in the company's compliance management. Executive-level misconduct has also tarnished corporate governance. According to penalty documents from the Heilongjiang bureau of the China Securities Regulatory Commission, former chairman Zhou Yunshu exploited insider information from industry collaborations to trade in Staidson shares, illegally profiting RMB 450,000. The regulator imposed penalties in September 2025, confiscating all illegal gains and levying an additional RMB 500,000 fine. Zhou, who had served for years overseeing R&D, sales, and overall operations as a core executive, saw his insider trading actions reveal gaps in compliance education at senior levels. The company's response, merely characterizing the incident as personal conduct without implementing systematic governance reforms, has done little to dispel market concerns about inadequate internal power oversight mechanisms.

Overseas production compliance issues have further constrained internationalization progress. In 2024, the US FDA issued two regulatory documents to Jiangsu Hengrui Pharmaceuticals Co., Ltd.: first, a Form 483 deficiency report citing lapses in production workshop data record management and insufficient quality supervision department performance; subsequently, a formal warning letter finding design flaws in sterile cleanroom facilities, with inadequate workshop isolation and airflow protection, and noting that submitted corrective plans failed to fully address system vulnerabilities. These repeated regulatory warnings have stalled the US filing progress for several oncology drugs, delaying overseas commercialization plans. In contrast, domestic peer BeiGene successfully navigated FDA approvals to achieve large-scale overseas sales, and Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s shortcomings in overseas production compliance have directly widened the internationalization gap within the industry.

Additionally, the wholly-owned subsidiary Jiangsu Xinchen Pharmaceutical has been repeatedly implicated in pharmaceutical commercial bribery cases. Court judgments from multiple regions reveal that subsidiary sales personnel bribed department heads at top-tier hospitals with cumulative payments of RMB 1.4 million in exchange for prescription volumes. These recurring violations indicate weak controls over terminal sales, with non-compliant promotional practices not fully eradicated, keeping compliance pressure pervasive across domestic channels.

Intensifying Industry Competition and Delayed Internationalization Slow Transformation

The combination of white-hot competition in the domestic innovative drug sector and sluggish overseas market expansion, layered onto internal operational deficiencies, is impeding Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s transformation strategy as a sector leader, with future growth potential continuing to narrow.

Homogeneous competition in the domestic innovative drug arena has reached a fever pitch, with crowded R&D pipelines targeting oncology, autoimmune, and metabolic pathways. Globally, there are over 5,000 clinical projects for PD-1 inhibitors alone, while dozens of domestic pharmaceutical companies are simultaneously developing ADC and bispecific antibody candidates. Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s core innovative drugs face comprehensive competitive threats: camrelizumab, apatinib, and other established products are steadily losing market share year after year, while new-generation ADC drugs are unlikely to achieve large-scale uptake in the short term. Multinational pharmaceutical companies continue to penetrate the domestic market—Roche and Merck are securing high-end market positions through localized pricing and hospital academic collaborations—while domestic players such as Innovent Biologics, BeiGene, and Junshi Biosciences persistently challenge oncology market share. The company's traditional market advantages are progressively eroding.

International expansion was intended as a core strategy to break free from domestic procurement constraints, but repeated FDA regulatory warnings and delayed drug filings have pushed overseas revenue growth off track. In the first half of 2026, overseas licensing revenue fell nearly 30% year-on-year, with rising overseas clinical and commercialization investments failing to yield returns. Peer BeiGene has achieved stable overseas profitability through zanubrutinib, with overseas revenue comprising a substantially larger share, whereas Jiangsu Hengrui Pharmaceuticals Co., Ltd. has yet to penetrate mainstream US and European markets. Years of building overseas clinical teams and collaborative resources have not translated into meaningful performance gains, and the internationalization strategy's implementation has fallen short of expectations.

The weakness of an expansive but underpowered R&D pipeline further amplifies competitive disadvantages. The company maintains over a hundred pipeline projects and more than four hundred clinical trials, appearing well-stocked on the surface. In reality, resources are fragmented, lacking benchmark blockbuster products. The RMB 8.7 billion R&D investment in 2025 was spread across over a hundred projects, averaging less than RMB 90 million per product—insufficient to concentrate resources on developing globally competitive proprietary drugs. Most pipeline candidates represent follow-on innovation, with competing products targeting the same mechanisms already completing clinical development, meaning any launch immediately faces intense price competition and inherently limited profit potential. These hefty R&D expenditures continue to consume working capital, perpetuating a cycle of "high investment, low returns."

With medical insurance and centralized procurement policies persistently shaping profit expectations, generic drug margins compressed to their limits, innovative drug price cuts becoming the norm, and sustained industry price competition, Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s path back to an era of high growth appears increasingly difficult. Investor confidence has waned, and valuation adjustments stemming from multiple compliance issues have taken their toll. The former hundred-billion-yuan pharma leader, now under the triple pressures of earnings, compliance, and internationalization, is seeing its industry-leading advantages gradually diminish, with operational adjustments likely to persist over the long term.